Dare Bioscience, Inc. annual report, FY2014

Filing summary

Entity discrepancy: The request identifies Dare Bioscience, Inc., but the supplied filing is Cerulean Pharma Inc.’s Form 10-K. This summary describes Cerulean’s filing, not a Dare Bioscience filing. The report covers the fiscal year ended December 31, 2014, and was filed March 19, 2015. The supplied text also includes unaudited quarterly data.

Business context and reporting period

Cerulean was a clinical-stage oncology company developing nanoparticle-drug conjugates (NDCs) using its Dynamic Tumor Targeting platform. Its lead candidate, CRLX101, was in Phase 2 development; CRLX301 entered Phase 1 in December 2014. The company had no product sales and relied principally on financing to fund operations.

Key financial metrics

MetricFY 2014FY 2013
Revenue$0.08 million$0.006 million
Research and development expense$11.772 million$9.700 million
General and administrative expense$8.587 million$6.166 million
Net loss$23.342 million$17.143 million
Net loss per share, basic and diluted$1.60$25.05
Net cash used in operating activities$19.061 million$16.614 million
Cash and cash equivalents at year-end$51.174 million$5.488 million
Working capital$44.775 million$(8.699) million
Long-term debt, including current portion$3.124 million$6.258 million

Operating loss was $20.279 million, compared with $15.860 million in 2013. No meaningful operating margin is evident given minimal revenue and continuing operating losses. The company reported no cash dividends and no off-balance-sheet arrangements.

Unaudited fourth-quarter 2014 revenue was zero and net loss was $7.467 million, versus revenue of $6,000 and net loss of $3.480 million in fourth-quarter 2013. Fourth-quarter 2014 operating expenses were $7.308 million, compared with $3.015 million a year earlier.

Financing activities provided $64.932 million in 2014, primarily reflecting $59.9 million of net IPO proceeds and convertible-note proceeds. At year-end, cash was largely held in money-market funds and certificates of deposit. Management estimated that year-end cash plus the January 2015 financing proceeds would fund operations, debt service, and capital needs into the third quarter of 2016; this was an estimate based on assumptions and not a guarantee.

Material changes versus prior periods

  • Revenue remained immaterial and was generated from research and material-transfer agreements, not product sales.
  • R&D expense increased 21% year over year, mainly because CRLX101 development and its renal-cell-carcinoma trial expanded. CRLX101 expense rose 55% to $7.235 million.
  • G&A expense increased 39%, primarily due to costs of operating as a public company, personnel, recruiting, and consulting.
  • Net loss grew 36%. Other expense included a $2.493 million loss on extinguishment of debt associated with conversion of convertible notes at the IPO.
  • The April 2014 IPO raised approximately $59.9 million net. Preferred stock and convertible notes converted into common stock, substantially changing the share count and making per-share comparisons across years less comparable.
  • Operating cash use rose from $16.614 million to $19.061 million, while year-end cash increased following the IPO.

Outlook, management commentary, and risks

  • CRLX101: The company-sponsored randomized Phase 2 trial in relapsed renal-cell carcinoma was ongoing. A separate 22-patient investigator-sponsored study met its four-month progression-free-survival endpoint; preliminary results reported median PFS of 9.9 months and a 23% partial response rate as of February 3, 2015. These were preliminary, single-arm results and require confirmation.
  • CRLX101 ovarian and rectal cancer studies were also ongoing. The rectal-cancer combination trial established a recommended Phase 2 dose, with enrollment in its expansion stage. Planned ovarian-cancer development included a trial combining CRLX101 with weekly paclitaxel.
  • CRLX301: A Phase 1 dose-escalation trial began in Australia in December 2014. Claims of increased tumor delivery and improved efficacy were preclinical and do not establish clinical benefit.
  • The company disclosed that a Phase 2 CRLX101 monotherapy trial in non-small-cell lung cancer failed its primary overall-survival endpoint; it did not plan further development in that indication. The company also acknowledged that CRLX101’s results fell short of its expectations.
  • Management expected increasing R&D and public-company expenses and continuing losses. The company had never generated product revenue and stated that substantial additional funding would be needed. It estimated runway into Q3 2016 using year-end cash and January 2015 proceeds.
  • On January 8, 2015, Cerulean borrowed $15 million from Hercules, repaid its Lighthouse debt, and sold $1 million of common stock to Hercules. Additional loan tranches of up to $11 million were conditional on clinical and financing milestones. The loan is secured by substantially all assets other than intellectual property, includes an IP negative pledge, and carries interest and repayment fees.
  • Key risks include clinical-trial failure or delay, slow patient enrollment, uncertain regulatory approval, need for further financing and dilution, dependence on third-party manufacturers and clinical investigators, and competition. The filing notes a prior CRLX301 manufacturing contamination issue and reliance on single suppliers at individual manufacturing stages.
  • Calando Pharmaceuticals was in Chapter 7 bankruptcy; its trustee sought authority to retain a broker to sell assets that included rights in license agreements with Cerulean. Cerulean reserved its rights and said current programs were not dependent on the affected licensed rights, while also disclosing potential risk to certain rights.
  • The former CEO resigned in October 2014, and the company was operating under transitional leadership. The Cambridge lease was due to expire in February 2016, with extension terms dependent on agreement about market rent.

Important facts for investors to verify

  • Confirm the intended issuer: the supplied filing is Cerulean Pharma Inc., not Dare Bioscience, Inc.
  • Review audited financial statements and subsequent-event disclosures, especially the January 2015 Hercules borrowing, debt repayment, collateral, covenants, and conditional tranches.
  • Check later clinical updates against the preliminary CRLX101 renal-cell-carcinoma and ovarian-cancer results, and distinguish investigator-sponsored data from company-sponsored randomized evidence.
  • Assess cash burn and financing needs against the company’s stated Q3 2016 runway estimate; the estimate depended on assumptions and additional milestone-conditioned financing was not assured.
  • Review the Calando bankruptcy proceedings and the status and enforceability of relevant licenses, alongside manufacturing supply and backup-source arrangements.
  • Interpret annual and quarterly per-share losses in light of the IPO-related share conversions and large change in weighted-average shares.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.